Back to top
more

Lineage Cell Therapeutics, Inc. (LCTX)

(Delayed Data from AMEX)

$1.54 USD

1.54
1,214,568

+0.02 (1.32%)

Updated Dec 3, 2020 04:00 PM ET

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.41%
2Buy17.88%
3Hold9.48%
4Sell5.03%
5Strong Sell1.87%
S&P50010.70%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth C Momentum F VGM

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 19% (205 out of 254)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Trades from $1

Balance Sheet

Research for LCTX

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

Fiscal Year End for Lineage Cell Therapeutics, Inc. falls in the month of December.

All items in Millions except Per Share data.

12/31/2019 12/31/2018 12/31/2017 12/31/2016 12/31/2015
Assets          
Cash & Equivalents 31 31 38 23 43
Receivables 24 4 3 1 2
Notes Receivable 0 0 0 0 0
Inventories 0 0 0 0 0
Other Current Assets 3 2 1 2 3
Total Current Assets 58 36 43 26 47
Net Property & Equipment 8 6 6 6 8
Investments & Advances 0 34 117 100 5
Other Non-Current Assets 0 0 0 0 0
Deferred Charges 0 0 0 0 0
Intangibles 59 3 7 10 34
Deposits & Other Assets 1 23 1 1 1
Total Assets 125 102 173 143 95
Liabilities & Shareholders Equity 12/31/2019 12/31/2018 12/31/2017 12/31/2016 12/31/2015
Notes Payable 0 0 0 1 0
Accounts Payable 5 6 6 7 9
Current Portion Long-Term Debt 0 0 0 0 0
Current Portion Capital Leases 1 0 0 0 0
Accrued Expenses 0 0 0 0 0
Income Taxes Payable 0 0 0 0 0
Other Current Liabilities 0 0 1 1 3
Total Current Liabilities 6 7 7 9 12
Mortgages 0 0 0 0 0
Deferred Taxes/Income 4 0 0 0 1
Convertible Debt 0 0 0 1 0
Long-Term Debt 0 0 0 0 0
Non-Current Capital Leases 0 0 0 0 0
Other Non-Current Liabilities 0 0 1 0 0
Minority Interest (Liabilities) 0 0 0 0 0
Total Liabilities 14 9 9 12 18
Shareholders Equity 12/31/2019 12/31/2018 12/31/2017 12/31/2016 12/31/2015
Preferred Stock 0 0 0 0 0
Common Stock (Par) 387 354 378 318 274
Capital Surplus 0 0 0 0 0
Retained Earnings -273 -262 -216 -196 -229
Other Equity -2 -0 2 12 49
Treasury Stock 0 0 0 3 18
Total Shareholder's Equity 111 92 164 131 76
Total Liabilities & Shareholder's Equity 125 102 173 143 95
Total Common Equity 111 92 164 131 76
Shares Outstanding 149.70 127.10 126.80 103.30 94.80
Book Value Per Share 0.74 0.73 1.30 1.26 0.81

Fiscal Year End for Lineage Cell Therapeutics, Inc. falls in the month of December.

All items in Millions except Per Share data.

9/30/2020 6/30/2020 3/31/2020 12/31/2019 9/30/2019
Assets          
Cash & Equivalents 38 20 26 31 36
Receivables 0 25 24 24 24
Notes Receivable 0 0 0 0 0
Inventories 0 0 0 0 0
Other Current Assets 1 1 2 3 2
Total Current Assets 40 46 52 58 62
Net Property & Equipment 5 7 8 8 9
Investments & Advances 0 0 0 0 0
Other Non-Current Assets 0 0 0 0 0
Deferred Charges 0 0 0 0 0
Intangibles 58 58 58 59 62
Deposits & Other Assets 1 1 1 1 1
Total Assets 103 112 119 125 133
Liabilities & Shareholders Equity 9/30/2020 6/30/2020 3/31/2020 12/31/2019 9/30/2019
Notes Payable 0 0 0 0 0
Accounts Payable 7 6 5 5 5
Current Portion Long-Term Debt 0 0 0 0 0
Current Portion Capital Leases 0 1 1 1 1
Accrued Expenses 0 0 0 0 0
Income Taxes Payable 0 0 0 0 0
Other Current Liabilities 0 0 0 0 0
Total Current Liabilities 8 8 7 6 6
Mortgages 0 0 0 0 0
Deferred Taxes/Income 3 3 3 4 7
Convertible Debt 0 0 0 0 0
Long-Term Debt 0 0 0 0 0
Non-Current Capital Leases 0 0 0 0 0
Other Non-Current Liabilities 0 0 0 1
Minority Interest (Liabilities) 0 0 0 0 0
Total Liabilities 13 14 14 14 17
Shareholders Equity 9/30/2020 6/30/2020 3/31/2020 12/31/2019 9/30/2019
Preferred Stock 0 0 0 0 0
Common Stock (Par) 388 388 388 387 386
Capital Surplus 0 0 0 0 0
Retained Earnings -296 -288 -282 -273 -269
Other Equity -2 -2 -1 -2 -2
Treasury Stock 0 0 0 0 0
Total Shareholder's Equity 90 98 105 111 116
Total Liabilities & Shareholder's Equity 103 112 119 125 133
Total Common Equity 90 98 105 111 116
Shares Outstanding 149.90 149.80 149.80 149.70 149.60
Book Value Per Share 0.60 0.65 0.70 0.74 0.77